pre-IPO PHARMA

COMPANY OVERVIEW

Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases. Founded by pioneers in Treg biology, T cell receptor, and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable. In addition to its lead program in progressive multiple sclerosis (MS), Abata has programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM) – two additional tissue-specific autoimmune diseases with substantial unmet need and a strong rationale for Abata’s Treg approach. The company was launched in 2021 by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital, and the JDRF T1D Fund. Abata is based in Cambridge, Mass.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Inflammatory Disease

  • WEBSITE

    https://abatatx.com/


    CAREER WEBSITE

    https://abatatx.com/join-us/


    SOCIAL MEDIA


    INVESTORS

    elevatebio invus jdrf lightspeed-venture-partners samsara-biocapital third-rock


    PRESS RELEASES


    Aug 28, 2023

    Abata Therapeutics to Present and Participate in Upcoming Investor and Industry Events


    Aug 24, 2023

    Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes


    May 31, 2023

    Abata Therapeutics to Present at Upcoming Investor and Industry Events in June


    Apr 20, 2023

    Abata Therapeutics Announces the Appointment of Leonard Dragone, M.D., Ph.D., as Chief Medical Officer


    Mar 9, 2023

    Abata Therapeutics Appoints David Kaufman, M.D., Ph.D., to its Board of Directors


    For More Press Releases


    Google Analytics Alternative